Literature DB >> 12615640

Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1.

I Kobsar1, M Berghoff, M Samsam, C Wessig, M Mäurer, K V Toyka, R Martini.   

Abstract

Mice heterozygously deficient for myelin protein zero (P0) mimicking human Charcot-Marie-Tooth (CMT) disease 1B show T-lymphocyte and macrophage upregulation in peripheral nerves, which aggravates and modulates the genetically mediated demyelinating neuropathy. In connexin32 (cx32)-deficient (cx32(def)) mice, which mimic the X-linked dominant form of CMT (CMTX), T-lymphocyte and macrophage numbers are also significantly elevated in peripheral nerves. To test the hypothesis that immune cells are indeed pathogenic in this model, we cross-bred cx32(def) mice with recombination activating gene-1 (RAG-1)-deficient mice, which lack mature T- and B-lymphocytes. In these immunoincompetent double mutants, the number of endoneurial macrophages was reduced. Furthermore, features indicative of myelin degeneration and axonopathic changes were mitigated in the RAG-1-deficient double mutants, whereas enlarged periaxonal Schwann cell collars, a hallmark specific for cx32-mutants, were not reduced. Since both cx32- and P0 deficiency lead to similar immunopathogenic processes, we conclude that immune-mediated demyelination may be a feature common to many CMT-like neuropathies independent of the genetic origin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615640     DOI: 10.1093/brain/awg072

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  30 in total

1.  The role of gap junctions in Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

2.  Gene therapy, CMT1X, and the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-14       Impact factor: 11.205

Review 3.  Animal models of autoimmune neuropathy.

Authors:  Betty Soliven
Journal:  ILAR J       Date:  2014

Review 4.  Molecular genetics of X-linked Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa; Steven S Scherer
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 5.  Role of immune cells in animal models for inherited peripheral neuropathies.

Authors:  Chi Wang Ip; Antje Kroner; Stefan Fischer; Martin Berghoff; Igor Kobsar; Mathias Mäurer; Rudolf Martini
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 6.  Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance.

Authors:  Mohtashem Samsam; Raheleh Ahangari; Saleh A Naser
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  A family with IVIg-responsive Charcot-Marie-Tooth disease.

Authors:  Yasuo Miki; Masahiko Tomiyama; Rie Haga; Haruo Nishijima; Chieko Suzuki; Aiichiro Kurihara; Kazuhiro Sugimoto; Akihiro Hashiguchi; Hiroshi Takashima; Masayuki Baba
Journal:  J Neurol       Date:  2012-12-12       Impact factor: 4.849

8.  The brain slice chamber, a novel variation of the Boyden Chamber Assay, allows time-dependent quantification of glioma invasion into mammalian brain in vitro.

Authors:  Christian Schichor; Siglinde Kerkau; Theresa Visted; Rudolf Martini; Rolf Bjerkvig; Jörg Christian Tonn; Roland Goldbrunner
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

9.  Motor and sensory neuropathy due to myelin infolding and paranodal damage in a transgenic mouse model of Charcot-Marie-Tooth disease type 1C.

Authors:  Samuel M Lee; Di Sha; Anum A Mohammed; Seneshaw Asress; Jonathan D Glass; Lih-Shen Chin; Lian Li
Journal:  Hum Mol Genet       Date:  2013-01-28       Impact factor: 6.150

10.  MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.

Authors:  Bianca Kohl; Stefan Fischer; Janos Groh; Carsten Wessig; Rudolf Martini
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.